This site is intended for healthcare professionals only.

This site is intended for healthcare professionals only.

Share with a colleague

Strapline if one is needed

Menu

Strapline if one is needed

About the program

Lennox-Gastaut Syndrome (LGS) is a complex and rare epileptic encephalopathy with multifactorial causes and diverse clinical presentations.

Through a series of six bite-sized ‘mini masterclass’ videos hosted by our expert faculty, this educational program aims to equip healthcare professionals with science-based insights into the pathophysiology, burden, and management of LGS. By enhancing diagnostic accuracy, promoting evidence-based and holistic treatment planning, and improving communication and decision-making with patients and caregivers, the program seeks to support earlier intervention, reduce caregiver burden, and improve long-term outcomes for those with LGS.

Content publication expected: January 2026, register to be notified upon its release

Register to be notified

Claim your CME credits

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™, awarded upon the successful completion of all six ‘mini masterclass’ videos. After viewing all episodes, participants will be directed to an evaluation form to provide feedback and formally claim their credits.

CME Credits icon

LGS Masterclasses

CME Credits icon
  • 15 minutes

Episode 1:

When the Seizures Don’t Stop: Recognizing Lennox-Gastaut Syndrome

International experts elucidate the neurophysiological and genetic factors underpinning Lennox-Gastaut syndrome, highlighting key pathophysiological processes.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese
CME Credits icon
  • 15 minutes

Episode 2:

More Than Seizures: Understanding the Full Burden of LGS

Our experts examine the burden of disease, offering a holistic view of the real-world burden of Lennox-Gastaut syndrome on patients and caregivers.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese
CME Credits icon
  • 15 minutes

Episode 3:

The Diagnostic Puzzle: Tools for Timely and Accurate LGS Identification

The faculty explore regional variations in Lennox-Gastaut syndrome diagnosis, highlighting current tools, barriers, and future innovations to improve early and accurate diagnosis across diverse healthcare settings.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese
CME Credits icon
  • 15 minutes

Episode 4:

Global Guidelines, Local Realities: LGS Diagnosis and Treatment Across Regions

International experts examine regional differences in Lennox-Gastaut syndrome diagnosis and treatment guidelines, identifying barriers and opportunities to align care across healthcare systems.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese
CME Credits icon
  • 15 minutes

Episode 5:

Managing the Storm: Evidence-Based Strategies for Treating LGS

The faculty explore regional treatment differences for Lennox-Gastaut syndrome, including therapy availability, mechanisms of action, and selection rationale, in order to optimize individualized care strategies.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese
CME Credits icon
  • 15 minutes

Episode 6:

What’s Missing in LGS Care? Barriers, Breakthroughs, and the Way Forward

The international experts discuss regional barriers to comprehensive, long-term care for Lennox-Gastaut syndrome, identifying system-level, cultural, and resource-based factors influencing treatment access and care coordination.

Translations available: 

Translations available: English, French, German, Italian, Spanish and Japanese

Learning objectives

Following completion of this independent educational program you will be able to:

  • Describe the neurophysiological and genetic factors underpinning LGS, highlighting key pathophysiological processes
  • Review the utility, accuracy, and limitations of current diagnostic tools in confirming a diagnosis of LGS and guiding treatment decisions
  • Compare diagnosis and treatment guidelines across key regions
  • Analyze the epidemiology, QOL impact, healthcare utilization, and caregiver challenges associated with LGS
  • Evaluate the range of pharmacologic and non-pharmacologic treatment strategies, including the rationale for therapy selection and combination approaches
  • Identify critical gaps in current treatment strategies for the long-term management of LGS across diverse healthcare settings

Target audience

This program is aimed at neurologists, pediatric neurologists, PCPs, advanced practice providers, and other HCPs involved in the care and management of patients with LGS.

Planning committee

In addition to the expert faculty, Springer Healthcare IME planners and staff include Rachel Goddard and Alessandra Geffner-Smith. The planning committee have no financial relationships to disclose.

All relevant financial relationships of the faculty have been mitigated.

Close
Andreea Nissenkorn

Andreea Nissenkorn

Wolfson Medical Center

Prof Andreea Nissenkorn is a Pediatric Neurologist leading a large clinic of children with epilepsy and rare genetic disorders. Her main research topics are epilepsy and autism caused by voltage gated sodium channels (SCN1a, SCN2a and SCN8a), and voltage gated potassium channels KCNQ2 and KCNQ3.

Prof Nissenkorn is especially interested in using bioinformatic methods and molecular dynamics simulation for predicting functional significance of pathogenic variants in voltage gated sodium and potassium channels, with direct implications for treatment in patients.

Additional research areas are translational medicine and personalized treatment, including N-of-1 trials with repurposed drugs.

Disclosures

Honoraria or consultation fees: MEDISON

Grants/research support: Neopharm

Close
Antonio Gil Nagel Rein

Antonio Gil-Nagel Rein

Ruber Internacional Hospital

Dr Antonio Gil-Nagel Rein is an international reference in epilepsy care and research, especially in the diagnosis and treatment of candidates for epilepsy surgery and epileptic and developmental encephalopathies (such as Lennox–Gastaut syndrome and Dravet syndrome). Having practiced neurology in the USA, he is Associated Head of the Neurology Department and, since 1998, Director of the Epilepsy Unit at the Ruber Internacional Hospital in Madrid, a pioneering center in the diagnosis and medical and surgical treatment of epilepsy in children and adults. Dr. Antonio Gil-Nagel is associated as a professor to IE University, he is Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB), directs the Chair of Epilepsy at the Francisco Vitoria University of Madrid and has led multiple clinical trials and scientific research in epilepsy. In addition to being a frequent speaker at national and international meetings, he is the author of several books on neurology, epilepsy and electroencephalography, and 202 articles.

Disclosures

Participation in a company sponsored speaker bureau: Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma , Jazz Pharmaceuticals, Longboard/Lunbeck, Oils 4 Cure, Praxis, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB, Zogenix, Xenon

Grants/research support: Biogen, Jazz Pharmaceuticals, PTC Therapeutics, UCB

Honoraria or consultation fees: Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma, Jazz Pharmaceuticals, Longboard/Lunbeck, Oils 4 Cure, Praxis, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB, Zogenix, Xenon

Close
Takamichi Yamamoto

Takamichi Yamamoto

Seirei Mikatahara General Hospital

Professor Takamichi Yamamoto graduated from the Hamamatsu University School of Medicine in 1986. He completed the Neurosurgical Residency Program at the Hamamatsu University Hospital and became a board-certified diplomate of the Japan Neurosurgical Society in 1992. He then moved to the United States to focus on epilepsy surgery as his subspecialty. He learned epilepsy surgery with a large number of cases at the New York University (NYU) Langone Medical Center under the supervision of Professor Werner K. Doyle. In addition, he also studied health services management and health policy at the NYU Wagner Graduate School of Public Service and earned a master’s degree in 2004. Then he came back to Japan and made the epilepsy surgery program. He ultimately created the Bethel Epilepsy Center at the Seirei Mikatahara General Hospital, the largest hospital in the prefecture. He has served as a hospital administrator since 2023.

Professor Yamamoto has published many original articles both as the first author and coauthor regarding pharmacotherapy for epilepsy including lamotrigine, perampanel, and cenobamate. He also wrote publications about epilepsy surgery and palliative treatment like vagus nerve stimulation. He obtained the title of FAES in 2017 from the American Epilepsy Society. He has been a member of the councilors in several societies related to epilepsy in Japan and has acted as one of the founding board members of the International Epilepsy Surgery Society (IESS) since 2022.

Disclosures

Honoraria or consultation fees: Eisai, UCB Japan, Daiichi-Sankyo, LivaNova Japan

Close
Andreea Nissenkorn

Andreea Nissenkorn

Wolfson Medical Center

Prof Andreea Nissenkorn is a Pediatric Neurologist leading a large clinic of children with epilepsy and rare genetic disorders. Her main research topics are epilepsy and autism caused by voltage gated sodium channels (SCN1a, SCN2a and SCN8a), and voltage gated potassium channels KCNQ2 and KCNQ3.

Prof Nissenkorn is especially interested in using bioinformatic methods and molecular dynamics simulation for predicting functional significance of pathogenic variants in voltage gated sodium and potassium channels, with direct implications for treatment in patients.

Additional research areas are translational medicine and personalized treatment, including N-of-1 trials with repurposed drugs.

Disclosures

Honoraria or consultation fees: MEDISON

Grants/research support: Neopharm

Close
Antonio Gil Nagel Rein

Antonio Gil-Nagel Rein

Ruber Internacional Hospital

Dr Antonio Gil-Nagel Rein is an international reference in epilepsy care and research, especially in the diagnosis and treatment of candidates for epilepsy surgery and epileptic and developmental encephalopathies (such as Lennox–Gastaut syndrome and Dravet syndrome). Having practiced neurology in the USA, he is Associated Head of the Neurology Department and, since 1998, Director of the Epilepsy Unit at the Ruber Internacional Hospital in Madrid, a pioneering center in the diagnosis and medical and surgical treatment of epilepsy in children and adults. Dr. Antonio Gil-Nagel is associated as a professor to IE University, he is Ad Honorem Professor at the Center for Biomedical Technology of the Polytechnic University of Madrid (CTB), directs the Chair of Epilepsy at the Francisco Vitoria University of Madrid and has led multiple clinical trials and scientific research in epilepsy. In addition to being a frequent speaker at national and international meetings, he is the author of several books on neurology, epilepsy and electroencephalography, and 202 articles.

Disclosures

Participation in a company sponsored speaker bureau: Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma , Jazz Pharmaceuticals, Longboard/Lunbeck, Oils 4 Cure, Praxis, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB, Zogenix, Xenon

Grants/research support: Biogen, Jazz Pharmaceuticals, PTC Therapeutics, UCB

Honoraria or consultation fees: Angelini Pharma, Bial, Biocodex, Eisai, Esteve, GW Pharma, Jazz Pharmaceuticals, Longboard/Lunbeck, Oils 4 Cure, Praxis, PTC Therapeutics, Rapport Therapeutics, Stoke, UCB, Zogenix, Xenon

Close
Takamichi Yamamoto

Takamichi Yamamoto

Seirei Mikatahara General Hospital

Professor Takamichi Yamamoto graduated from the Hamamatsu University School of Medicine in 1986. He completed the Neurosurgical Residency Program at the Hamamatsu University Hospital and became a board-certified diplomate of the Japan Neurosurgical Society in 1992. He then moved to the United States to focus on epilepsy surgery as his subspecialty. He learned epilepsy surgery with a large number of cases at the New York University (NYU) Langone Medical Center under the supervision of Professor Werner K. Doyle. In addition, he also studied health services management and health policy at the NYU Wagner Graduate School of Public Service and earned a master’s degree in 2004. Then he came back to Japan and made the epilepsy surgery program. He ultimately created the Bethel Epilepsy Center at the Seirei Mikatahara General Hospital, the largest hospital in the prefecture. He has served as a hospital administrator since 2023.

Professor Yamamoto has published many original articles both as the first author and coauthor regarding pharmacotherapy for epilepsy including lamotrigine, perampanel, and cenobamate. He also wrote publications about epilepsy surgery and palliative treatment like vagus nerve stimulation. He obtained the title of FAES in 2017 from the American Epilepsy Society. He has been a member of the councilors in several societies related to epilepsy in Japan and has acted as one of the founding board members of the International Epilepsy Surgery Society (IESS) since 2022.

Disclosures

Honoraria or consultation fees: Eisai, UCB Japan, Daiichi-Sankyo, LivaNova Japan